1-20 of 65
Term: Adult Clinical Trials – Non-Immunologic
Volume: 20
Issue: suppl_6
Journal Article
ACTR-49. PriCoTTF: A PHASE I/II TRIAL OF TUMOR TREATING FIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi22–vi23, https://doi.org/10.1093/neuonc/noy148.081
Published: 05 November 2018
Journal Article
ACTR-58. TREATMENT OUTCOMES OF STEREOTACTIC RADIOTHERAPY COMBINED WITH BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi24, https://doi.org/10.1093/neuonc/noy148.089
Published: 05 November 2018
Journal Article
ACTR-59. IMPROVING THE INTRA-OPERATIVE DIAGNOSIS OF HIGH-GRADE GLIOMA USING A FLUORESCENCE BIOMARKER – RESULT OF THE GALA-BIDD STUDY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi24–vi25, https://doi.org/10.1093/neuonc/noy148.090
Published: 05 November 2018
Journal Article
ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi25, https://doi.org/10.1093/neuonc/noy148.091
Published: 05 November 2018
Journal Article
ACTR-62. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi25, https://doi.org/10.1093/neuonc/noy148.092
Published: 05 November 2018
Journal Article
ACTR-64. OBJECTIVE RESPONSES TO CHEMOTHERAPY IN RECURRENT GLIOMA DO NOT PREDICT BETTER SURVIVAL: A PROSPECTIVE ANALYSIS FROM THE GERMAN GLIOMA NETWORK
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi26, https://doi.org/10.1093/neuonc/noy148.094
Published: 05 November 2018
Journal Article
ACTR-65. INTRATHECAL PEMETREXED FOR PATIENTS WITH RECURRENT LEPTOMENINGEAL METASTASIS FROM LUNG ADENOCARCINOMA: A PHASE I CLINICAL TRIAL (IPRLM,NCT03101579)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi26, https://doi.org/10.1093/neuonc/noy148.095
Published: 05 November 2018
Journal Article
ACTR-66. BEVACIZUMAB THERAPY FOR THE TREATMENT OF ADULT GLIOBLASTOMA: SYSTEMATIC REVIEW & META-ANALYSIS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi26, https://doi.org/10.1093/neuonc/noy148.096
Published: 05 November 2018
Journal Article
ACTR-19. A MULTICENTER PILOT PHASE II STUDY OF CONTINUING TMZ WITH THE ADDITION OF DISULFIRAM AND COPPER FOR REFRACTORY GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi15, https://doi.org/10.1093/neuonc/noy148.053
Published: 05 November 2018
Journal Article
ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 – FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi15, https://doi.org/10.1093/neuonc/noy148.054
Published: 05 November 2018
Journal Article
ACTR-21. MANAGEMENT OF OCULAR SIDE EFFECTS IN PATIENTS WITH EGFR-AMPLIFIED GLIOBLASTOMA RECEIVING DEPATUXIZUMAB MAFODOTIN
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi15–vi16, https://doi.org/10.1093/neuonc/noy148.055
Published: 05 November 2018
Journal Article
ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi16–vi17, https://doi.org/10.1093/neuonc/noy148.059
Published: 05 November 2018
Journal Article
ACTR-29. KETOGENIC DIETS AS AN ADJUVANT THERAPY IN GLIOBLASTOMA (KEATING): A MIXED METHOD APPROACH TO ASSESSING TRIAL FEASIBILITY.
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi17, https://doi.org/10.1093/neuonc/noy148.062
Published: 05 November 2018
Journal Article
ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi18–vi19, https://doi.org/10.1093/neuonc/noy148.066
Published: 05 November 2018
Journal Article
ACTR-37. SHORT-TERM BEVACIZUMAB FOR RECURRENT GLIOBLASTOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi19–vi20, https://doi.org/10.1093/neuonc/noy148.070
Published: 05 November 2018
Journal Article
ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi21, https://doi.org/10.1093/neuonc/noy148.075
Published: 05 November 2018
Journal Article
ACTR-46. HIGHER DOSES OF TTFIELDS IN THE TUMOR ARE ASSOCIATED WITH IMPROVED PATIENT OUTCOME
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi21–vi22, https://doi.org/10.1093/neuonc/noy148.078
Published: 05 November 2018
Journal Article
ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi22, https://doi.org/10.1093/neuonc/noy148.079
Published: 05 November 2018
Journal Article
ACTR-48. FEASIBILITY OF DISCONTINUATION OF ADJUVANT TEMOZOLOMIDE AFTER 12 CYCLES REMAINING WITHOUT PROGRESSION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi22, https://doi.org/10.1093/neuonc/noy148.080
Published: 05 November 2018
Journal Article
ACTR-07. COMPLETE, DURABLE RESPONSE OF A RECURRENT UNRESECTABLE GRADE III GLIOMA TO A REPURPOSED DRUG REGIMEN
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi12, https://doi.org/10.1093/neuonc/noy148.042
Published: 05 November 2018
